In a patient with a 3-year history of bilateral ear fullness, normal audiometry, and visible middle‑ear effusion that began after COVID‑19 infection, what is the recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Persistent Bilateral Middle Ear Effusion Following COVID-19

For a patient with 3-year persistent bilateral middle ear effusion (OME) post-COVID-19 and normal audiometry, initiate treatment with intranasal corticosteroids combined with nasal decongestants, and if no improvement occurs within 4-6 weeks, proceed to bilateral myringotomy with tympanocentesis.

Understanding Post-COVID OME

The temporal relationship between COVID-19 infection and your patient's ear symptoms is clinically significant. Recent evidence demonstrates that SARS-CoV-2 can directly infect middle ear spaces and persist in middle ear fluid significantly longer than in the upper respiratory tract 1. In one study, the virus was detected in middle ear effusions for an average of 28.65 days, with some patients showing viral presence in the middle ear even when nasal swabs were negative 2.

The incidence of OME increased dramatically during the COVID-19 pandemic—from baseline rates of 2.2-2.5% to 9.5% of all otolaryngology patients 1. Peak incidence typically occurred one week post-infection, though your patient's 3-year duration represents a chronic presentation requiring more aggressive management.

Initial Treatment Approach

First-Line Medical Management

Start with:

  • Intranasal corticosteroids (e.g., mometasone furoate or fluticasone propionate) twice daily
  • Nasal decongestants (topical oxymetazoline for maximum 3-5 days, then oral pseudoephedrine if needed)
  • Oral corticosteroids may be considered, though earlier pandemic guidance cautioned against systemic steroids due to concerns about viral shedding 3—this is less relevant 3 years post-infection

The integrated treatment approach (combining nasal steroids, decongestants, and when appropriate, oral steroids) achieved an 83.6% cure rate in post-COVID OME patients 4.

Timeline for Response

  • Reassess at 2-4 weeks with repeat otoscopy and tympanometry
  • If no improvement by 4-6 weeks, proceed to surgical intervention
  • The 3-year chronicity in your patient suggests medical therapy alone will likely be insufficient

Surgical Intervention

Myringotomy with Tympanocentesis

Given the chronicity, your patient will likely require:

  1. Bilateral myringotomy with aspiration of middle ear fluid

    • This both provides diagnostic material and therapeutic drainage
    • In post-COVID OME studies, 31 of 52 patients (59.6%) were cured after a single tympanocentesis 1
    • However, 21 patients required two or more procedures

  2. Consider tympanostomy tube placement if:

    • Recurrence occurs after initial myringotomy
    • Effusion persists beyond 3 months despite treatment
    • The patient develops conductive hearing loss (though your patient currently has normal audiometry)

Important Surgical Considerations

The 3-year duration raises concern for potential middle ear changes. However, recent evidence is reassuring: even in cases of severe post-COVID auditory complications, cochlear fibrosis or ossification has not been consistently observed 5. Still, be prepared for:

  • Thickened, viscous middle ear fluid
  • Possible poor mastoid pneumatization (associated with worse outcomes) 1
  • Need for repeat procedures in 40% of cases 1

Prognostic Factors

Favorable Indicators

Your patient has several positive prognostic factors:

  • Normal hearing (most post-COVID OME patients with conductive hearing loss still recover well) 6, 7
  • No comorbidities mentioned (hypertension and diabetes worsen outcomes) 1

Expected Outcomes

Based on recent data 4, 7:

  • Complete resolution: 60-65% of patients
  • Improvement without full cure: 30-31% of patients
  • No improvement: 5-10% of patients
  • Recurrence rate: 8.2% within 2-3 months post-treatment

The fact that your patient has normal audiometry despite 3 years of effusion is unusual but favorable—it suggests the effusion may be thin rather than thick/mucoid, which typically responds better to treatment.

Follow-Up Protocol

After initiating treatment:

  • Week 2-4: Otoscopy and tympanometry to assess response
  • Month 3: Comprehensive evaluation including repeat audiometry
  • Months 6 and 12: Monitor for recurrence, as 8.2% of post-COVID OME patients experience late relapse 4

Key Clinical Pitfalls

  1. Don't assume resolution without intervention: The 3-year duration indicates this will not spontaneously resolve
  2. Don't delay surgical referral: If medical management fails at 4-6 weeks, prolonged observation is unlikely to help
  3. Monitor for hearing changes: While currently normal, conductive hearing loss can develop and requires more aggressive intervention
  4. Screen for nasopharyngeal pathology: Chronic unilateral or bilateral OME in adults warrants nasopharyngoscopy to exclude nasopharyngeal mass, though bilateral presentation post-COVID makes this less likely

The combination of temporal relationship to COVID-19, bilateral presentation, and 3-year chronicity strongly suggests post-viral Eustachian tube dysfunction as the underlying mechanism, which typically responds well to the outlined treatment algorithm.

References

6
Research

Impact of COVID-19 on the treatment outcomes of secretory otitis media.

Journal of infection in developing countries, 2026

Related Questions

In a 47-year-old man with post‑viral acute otitis media presenting with ear pressure, hearing loss, low‑grade fever, tympanic membrane erythema without discharge, and no mastoid tenderness, which of the following statements is NOT correct?
How should I manage ear congestion in a 73-year-old who had a recent upper respiratory infection and a flight two weeks ago, now experiencing bilateral ear fullness (left greater than right) with no cerumen?
In a 23‑year‑old with hundreds of colonic polyps and no family history of polyps in the past two generations, could this represent familial adenomatous polyposis (FAP) or another hereditary polyposis syndrome, and how might it occur without a known familial pattern?
What is the recommended maintenance monitoring schedule for clozapine, including CBC/ANC frequency and metabolic assessments?
What is the appropriate dosing of trimethoprim‑sulfamethoxazole (Bactrim) for a male patient with a urinary tract infection and chronic kidney disease stage 3b?
What is the appropriate physical examination of the foot when a metatarsal fracture is suspected?
In a patient with a mechanical mitral valve replacement on warfarin who is scheduled for cataract surgery, is heparin bridging required?
What pharmacologic treatment is recommended for an adult with bulimia nervosa who has no contraindications to selective serotonin reuptake inhibitors?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.